Viewing Study NCT00005467


Ignite Creation Date: 2025-12-25 @ 12:53 AM
Ignite Modification Date: 2025-12-26 @ 1:29 PM
Study NCT ID: NCT00005467
Status: COMPLETED
Last Update Posted: 2016-02-18
First Post: 2000-05-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Indices of Severity and Prognosis for Sickle Cell Disease
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Organization:

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2000-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To develop a clinical severity index that could prospectively identify sickle cell disease patients who were at high risk for a turbulent clinical course and a poor prognosis.
Detailed Description: DESIGN NARRATIVE:

Using the database, univariate analysis showed that factors associated with the occurrence of cerebrovascular accident (51 patients) included hematocrit, rate of change of pocked red cell count, and polymer fraction at 40 percent oxygen saturation (PF40). Only low hematocrit was predictive of death in the pediatric cohort. There were 45 disease-related deaths.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
R01HL042498 NIH None https://reporter.nih.gov/quic… View